Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Digestive Diseases and Sciences|November 14, 2019
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative ColitisFabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2016
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study"Walter Fries, Anna Viola, Natalia Manetti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 20, 2023
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD studyDavide Giuseppe Ribaldone, Laura Parisio, Angela Variola, et al.
Inflammatory Bowel Diseases|April 2, 2022
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational StudyGaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
Nature Genetics|January 6, 2009
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association studyMark S Silverberg, Judy H Cho, John D Rioux, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
United European Gastroenterology Journal|October 19, 2020
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of careSimone Saibeni, Ludovica Scucchi, Gabriele Dragoni, et al.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Reviews on Recent Clinical Trials|June 15, 2021
Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary CareAntonio Tursi, Marcello Picchio, Walter Elisei, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Pageof 9